AKT1 and neoplasm: Besides inducing PTEN expression, pioglitazone also intensified the tumour‐killing effect of arsenic trioxide (ATO) in leukaemia via the suppression of PI3K/AKT pathway,113 and mTOR inhibitor rapamycin has been shown to enhance the effects of rosiglitazone in inhibiting non‐small cell lung carcinoma (NSCLC) cell proliferation in vivo.111